Biohaven Net Income from 2010 to 2026
| BHVN Stock | USD 11.49 0.01 0.09% |
Net Loss | First Reported 2017-03-31 | Previous Quarter -198.1 M | Current Value -173.4 M | Quarterly Volatility 85.3 M |
Check Biohaven Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biohaven Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.5 M, Interest Expense of 1.2 M or Selling General Administrative of 86.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.6. Biohaven financial statements analysis is a perfect complement when working with Biohaven Pharmaceutical Valuation or Volatility modules.
Biohaven | Net Income | Build AI portfolio with Biohaven Stock |
Evaluating Biohaven Pharmaceutical's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Biohaven Pharmaceutical Holding's fundamental strength.
Latest Biohaven Pharmaceutical's Net Income Growth Pattern
Below is the plot of the Net Income of Biohaven Pharmaceutical Holding over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Biohaven Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Biohaven Pharmaceutical Holding operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Biohaven Pharmaceutical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biohaven Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (846.42 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Biohaven Net Income Regression Statistics
| Arithmetic Mean | (525,344,330) | |
| Coefficient Of Variation | (32.85) | |
| Mean Deviation | 98,282,469 | |
| Median | (528,805,000) | |
| Standard Deviation | 172,599,809 | |
| Sample Variance | 29790.7T | |
| Range | 727.8M | |
| R-Value | (0.21) | |
| Mean Square Error | 30409.2T | |
| R-Squared | 0.04 | |
| Significance | 0.42 | |
| Slope | (7,090,740) | |
| Total Sum of Squares | 476651.1T |
Biohaven Net Income History
Other Fundumenentals of Biohaven Pharmaceutical
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Biohaven Pharmaceutical Net Income component correlations
About Biohaven Pharmaceutical Financial Statements
Biohaven Pharmaceutical investors utilize fundamental indicators, such as Net Income, to predict how Biohaven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -761.8 M | -723.7 M | |
| Net Loss | -761.8 M | -799.9 M | |
| Net Loss | -513.3 M | -538.9 M | |
| Net Loss | (10.67) | (11.20) | |
| Net Income Per E B T | 1.15 | 1.10 |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Biohaven Stock
Moving against Biohaven Stock
| 0.67 | OSE | OSE Pharma SA | PairCorr |
| 0.59 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.56 | DRMA | Dermata Therapeutics | PairCorr |
| 0.5 | VCEL | Vericel Corp Ord | PairCorr |
| 0.42 | ABNX | Abionyx Pharma SA | PairCorr |
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Biohaven Pharmaceutical Correlation against competitors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Biotechnology sector continue expanding? Could Biohaven diversify its offerings? Factors like these will boost the valuation of Biohaven Pharmaceutical. Projected growth potential of Biohaven fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biohaven Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Biohaven Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biohaven's accounting equity. The concept of intrinsic value - what Biohaven Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biohaven Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biohaven Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biohaven Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biohaven Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.